GSK pulls Votrient in ovarian cancer, clears way for AZ's olaparib
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has pulled its European submission for approval of Votrient (pazopanib) in advanced ovarian cancer and will not be pursuing this indication globally. The decision comes after disappointing overall survival data.